A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.
Ian W. Flinn(Tennessee Oncology), Albert S. Yu(Unknown), John E. Leonard, Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Steven Coutré(Georgetown University), Marshall T. Schreeder(Clearview Cancer Institute), Shoko Vos(Radboud University Nijmegen), L. L. Miller, Sissy Peterman, Ralph V. Boccia(Center for Cancer and Blood Disorders), Leanne Holes(Gilead Sciences (United States))
Cited by 18
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k